Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 15/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | MARK3 | P27448 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.48 |
| ▸ | BRSK2 | Q8IWQ3 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | ULK1 | O75385 | 2/20 | 0.47 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.47 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386204 | 0.90 | TBK1 (0.67) | TBK1PDPK1SYKMARK3CDK2 | |
| SCHEMBL3388973 | 0.90 | TBK1 (0.54) | TBK1PDPK1SYKMARK3CDK2 | |
| SCHEMBL3386107 | 0.89 | TBK1 (0.56) | TBK1PDPK1SYKMARK3IKBKE | |
| SCHEMBL3385954 | 0.89 | TBK1 (0.53) | TBK1PDPK1SYKMARK3CDK2 | |
| SCHEMBL3389588 | 0.88 | TBK1 (0.54) | TBK1PDPK1SYKMARK3IKBKE | |
| SCHEMBL3389513 | 0.88 | TBK1 (0.54) | TBK1PDPK1SYKMARK3IKBKE | |
| SCHEMBL3383879 | 0.88 | TBK1 (0.69) | TBK1PDPK1SYKMARK3IKBKE | |
| SCHEMBL3387756 | 0.87 | SYK (0.53) | TBK1PDPK1SYKMARK3CDK2 | |
| SCHEMBL3384474 | 0.87 | ULK1 (0.54) | TBK1PDPK1SYKMARK3CDK2 | |
| SCHEMBL3389556 | 0.87 | TBK1 (0.66) | TBK1PDPK1SYKMARK3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | TBK1 2898/4885PDPK1 2468/4885SYK 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.